Article · 5 Dec 2023
EditorialPublished 2014
Why Single Pharmacogenomic Trials Should be Very Significant?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Recasting traditional frequentist thinking into Bayesian beliefs illustrates that requirements for 'strength of evidence' should drive the sizing of pharmacogenomic trials not hopeful hyperbolae. There is no 'free lunch' in pharmacogenomic investigations.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 2017
Pharmacogenomics: A Step towards Advancing Clinical Trials
Conference abstract · 3 Aug 2015
Pharmacogenomics: The future of clinical trials, new product development and the practice of medicine
Review article · 2012
Clinical Trials in Cancer and Pharmacogenomics: A Critical Evaluation
Editorial · 2012
Cancer Clinical Trials Optimization and Pharmacogenomics
More from this journal
The newest in Journal of Pharmacogenomics & Pharmacoproteomics.
Article · 31 Dec 2025
Molecular Phenotyping: Integrated Biological Profiles for Understanding Cellular Function and Disease
Article · 31 Dec 2025
Genetic Determinants of Individual Drug Response
Article · 31 Dec 2025
Genetic Variation in Drug Metabolism, Transport, and Treatment Response
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacogenomics & Pharmacoproteomics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Clive E Bowman”

